San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).
San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).
Posted in Melanoma News, Health Professionals, Clinical Trials
Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.
Posted in Melanoma News, Health Professionals, Clinical Trials
A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.
Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News
A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.
Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News